Non-bacterial thrombotic endocarditis in ROS1-rearranged lung cancer: a report of two cases

被引:0
作者
Recuero-Borau, Jordi [1 ,2 ]
Masfarre, Laura [1 ]
Navarro, Nil [1 ]
Rocha, Pedro [1 ]
Taus, Alvaro [1 ]
Arriola, Edurne [1 ]
机构
[1] Hosp Del Mar, Dept Med Oncol, Barcelona, Spain
[2] Hosp Del Mar, Dept Med Oncol, Pg Maritim Barceloneta 25 29, Barcelona 08003, Spain
关键词
Non -small -cell lung carcinoma; endocarditis; ROS1; protein; human; case report;
D O I
10.21037/tlcr-23-412
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Lung cancer is one of the tumor types with highest incidence of thromboembolic events (TE), especially adenocarcinoma subtype. ROS1 rearrangements confer higher risk of TE. Non-bacterial thrombotic endocarditis (NBTE) is a rare event, frequently diagnosed on autopsy. Clinical suspicion is key to reach the diagnosis and start early treatment of the underlying cause and anticoagulation in order to improve patients' outcomes. Case Description: Here we present two cases of NBTE in patients with ROS1-rearranged lung cancer with different clinical debuts. A 42-year-old woman presented initial tetraplegia and impaired level of consciousness, and the other patient, a 54-year-old man, was diagnosed of stroke with sensitive loss of left body. Both were diagnosed of NBTE, confirmed by the finding of cardiac vegetation on echocardiogram and no microorganisms found on blood cultures. Both responded well to targeted therapy with lorlatinib and crizotinib and anticoagulation with heparin. Conclusions: NBTE is an infrequent disease which can cause severe neurological symptoms that impair quality of life, performance status and survival. Early clinical suspicion in patients with higher risk of TEs such as patients with rearrangements of ROS1 gene is of essence. Adequate management of underlying disease and anticoagulation may impact in the recovery of symptoms.
引用
收藏
页码:179 / 185
页数:7
相关论文
共 10 条
  • [1] Cheung Brian, 2020, Eur J Case Rep Intern Med, V7, P001798, DOI 10.12890/2020_001798
  • [2] Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib
    Facchinetti, Francesco
    Levy, Antonin
    Ammari, Samy
    Naltet, Charles
    Lavaud, Pernelle
    Aldea, Mihaela
    Vasseur, Damien
    Planchard, David
    Besse, Benjamin
    [J]. CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 2805 - 2810
  • [3] The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria
    Fowler Jr, Vance G.
    Durack, David T.
    Selton-Suty, Christine
    Athan, Eugene
    Bayer, Arnold S.
    Chamis, Anna Lisa
    Dahl, Anders
    DiBernardo, Louis
    Durante-Mangoni, Emanuele
    Duval, Xavier
    Fortes, Claudio Querido
    Fosbol, Emil
    Hannan, Margaret M.
    Hasse, Barbara
    Hoen, Bruno
    Karchmer, Adolf W.
    Mestres, Carlos A.
    Petti, Cathy A.
    Pizzi, Maria Nazarena
    Preston, Stephen D.
    Roque, Albert
    Vandenesch, Francois
    van der Meer, Jan T. M.
    van der Vaart, Thomas W.
    Miro, Jose M.
    [J]. CLINICAL INFECTIOUS DISEASES, 2023, 77 (04) : 518 - 526
  • [4] Nonbacterial Thrombotic Endocarditis Pathogenesis, Diagnosis, and Management
    Liu, Joshua
    Frishman, William H.
    [J]. CARDIOLOGY IN REVIEW, 2016, 24 (05) : 244 - 247
  • [5] High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations
    Liu, Yiwei
    Wang, Wanying
    Wu, Fengying
    Gao, Guanghui
    Xu, Jian
    Li, Xuefei
    Zhao, Chao
    Yang, Shuo
    Mao, Shiqi
    Pan, Yingying
    Jia, Keyi
    Shao, Chuchu
    Chen, Bin
    Ren, Shengxiang
    Zhou, Caicun
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (03) : 1512 - +
  • [6] American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
    Lyman, Gary H.
    Carrier, Marc
    Ay, Cihan
    Di Nisio, Marcello
    Hicks, Lisa K.
    Khorana, Alok A.
    Leavitt, Andrew D.
    Lee, Agnes Y. Y.
    Macbeth, Fergus
    Morgan, Rebecca L.
    Noble, Simon
    Sexton, Elizabeth A.
    Stenehjem, David
    Wiercioch, Wojtek
    Kahale, Lara A.
    Alonso-Coello, Pablo
    [J]. BLOOD ADVANCES, 2021, 5 (04) : 927 - 974
  • [7] Association of anticoagulant use with clinical outcomes from crizotinib in ALK- and ROS1-rearranged advanced non-small cell lung cancers: A retrospective analysis of PROFILE 1001
    Ng, Terry L.
    Tsui, David C. C.
    Wang, Sherry
    Usari, Tiziana
    Patil, Tejas
    Wilner, Keith
    Camidge, David R.
    [J]. CANCER MEDICINE, 2022, 11 (23): : 4422 - 4429
  • [8] ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events
    Ng, Terry L.
    Smith, Derek E.
    Mushtaq, Rao
    Patil, Tejas
    Dimou, Anastasios
    Yang, Shuo
    Liu, Qian
    Li, Xuefei
    Zhou, Caicun
    Jones, Robert T.
    Tu, Megan M.
    Yan, Flora
    Bowman, I. Alex
    Liu, Stephen, V
    Newkirk, Siera
    Bauml, Joshua
    Doebele, Robert C.
    Aisner, Dara L.
    Gao, Dexiang
    Ren, Shengxiang
    Camidge, D. Ross
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (04) : 596 - 605
  • [9] Contemporary demographics, diagnostics and outcomes in non-bacterial thrombotic endocarditis
    Quintero-Martinez, Juan A.
    Hindy, Joya-Rita
    El Zein, Said
    Michelena, Hector, I
    Nkomo, Vuyisile T.
    DeSimone, Daniel C.
    Baddour, Larry M.
    [J]. HEART, 2022, 108 (20) : 1637 - 1643
  • [10] Lung Cancer as a Leading Cause among Paraneoplastic Non-Bacterial Thrombotic Endocarditis: A Meta-Analysis of Individual Patients' Data
    Rahouma, Mohamed
    Khairallah, Sherif
    Dabsha, Anas
    Elkharbotly, Ismail A. M. H.
    Baudo, Massimo
    Ismail, Amr
    Korani, Omnia M.
    Hossny, Mohamed
    Dimagli, Arnaldo
    Girardi, Leonard N.
    Mick, Stephanie L.
    Gaudino, Mario
    [J]. CANCERS, 2023, 15 (06)